Drugplain

IMULDOSA 130 mg/26mL

ustekinumab-srlf · INJECTION · Accord BioPharma Inc.

No Recall History
Plain English

IMULDOSA is a injection containing ustekinumab-srlf at 130 mg/26mL, taken intravenous. Manufactured by Accord BioPharma Inc..

Key Facts

Brand Name
IMULDOSA
Generic Name
ustekinumab-srlf
NDC Code (Product)
69448-019
Manufacturer
Accord BioPharma Inc.
Strength
130 mg/26mL
Dosage Form
INJECTION
Route
INTRAVENOUS
Marketing Status
Application #
BLA761364
Marketing Start
10/18/2024

Recall History

No Recall History

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

colitis ulcerative1 reports
ear infection staphylococcal1 reports
ear pain1 reports
fatigue1 reports
groin abscess1 reports
hypoacusis1 reports
malaise1 reports
middle ear effusion1 reports
oral mucosal blistering1 reports
periodontitis1 reports

Frequently Asked Questions

What is IMULDOSA used for?

IMULDOSA contains ustekinumab-srlf. It is a injection taken intravenous. Consult your doctor for specific uses.

Is IMULDOSA a controlled substance?

IMULDOSA is not classified as a controlled substance by the DEA.

What is the generic name for IMULDOSA?

The generic name for IMULDOSA is ustekinumab-srlf. There are no other listed brand versions of ustekinumab-srlf.

What is the NDC code for IMULDOSA 130 mg/26mL?

The NDC (National Drug Code) for IMULDOSA 130 mg/26mL is 69448-019, listed by Accord BioPharma Inc..

Product NDC

69448-019

Package NDC

69448-019-26

Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.

Data from openFDA · Public domain (CC0 1.0)